Vault-13

FRAZIER MANAGEMENT LLC

SEATTLE, WA · CIK 1032165 · 13F filing filed 2020-08-04

No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.

As an employer

US visa salary filings

Job titleFilingsMedianRange
Associate, Investment AnalystSeattle, WA 1 $125,000

Source: US Department of Labor, Labor Condition Application disclosure data (certified, full-time, yearly equivalent). These are the salaries the employer committed to pay the visa roles it filed for, at least the prevailing wage for the job and place; they are not the pay of all its staff. Filed by: Frazier Management LLC.

$1.1bn reported value +29.1% vs Q1 2020
26positions
86.4%in top 10
2 new 4 added 3 reduced 1 sold out vs Q1 2020

Holdings, Q2 2020

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 ARCUTIS BIOTHERAPEUTICS INC COM ARQT ARQT 10,542,790 $318.8m28.00% 28.00% UnchangedShares held: Q4 2019 0, Q1 2020 10.5m, Q2 2020 10.5m
2 PHATHOM PHARMACEUTICALS INC COM PHAT PHAT 5,827,415 $191.8m16.84% 16.84% ReducedShares held: Q4 2019 7.3m, Q1 2020 7.3m, Q2 2020 5.8m -1.5m -1,456,854 -20.0%
3 PASSAGE BIO INC COM COM 5,009,219 $136.9m12.02% 12.02% UnchangedShares held: Q4 2019 0, Q1 2020 5.0m, Q2 2020 5.0m
4 VAXCYTE INC COM PCVX PCVX 2,309,554 $73.0m6.41% 6.41% NewShares held: Q4 2019 0, Q1 2020 0, Q2 2020 2.3m
5 MIRUM PHARMACEUTICALS INC COM MIRM MIRM 3,566,912 $69.4m6.10% 6.10% UnchangedShares held: Q4 2019 3.6m, Q1 2020 3.6m, Q2 2020 3.6m
6 ANAPTYSBIO INC COM ANAB ANAB 2,316,447 $51.7m4.54% 4.54% UnchangedShares held: Q4 2019 2.3m, Q1 2020 2.3m, Q2 2020 2.3m
7 TRANSLATE BIO INC COM COM 2,182,789 $39.1m3.43% 3.43% UnchangedShares held: Q4 2019 2.2m, Q1 2020 2.2m, Q2 2020 2.2m
8 KRYSTAL BIOTECH INC COM KRYS KRYS 895,000 $37.1m3.26% 3.26% UnchangedShares held: Q4 2019 895.0k, Q1 2020 895.0k, Q2 2020 895.0k
9 IOVANCE BIOTHERAPEUTICS INC COM IOVA IOVA 1,312,999 $36.0m3.16% 3.16% ReducedShares held: Q4 2019 1.8m, Q1 2020 1.8m, Q2 2020 1.3m -437.7k -437,666 -25.0%
10 ADVERUM BIOTECHNOLOGIES INC COM COM 1,437,028 $30.0m2.63% 2.63% AddedShares held: Q4 2019 268.3k, Q1 2020 1.3m, Q2 2020 1.4m +158.7k +158,700 12.4%
11 ALPINE IMMUNE SCIENCES INC COM NVLS NVLS 2,571,450 $25.0m2.19% 2.19% UnchangedShares held: Q4 2019 2.6m, Q1 2020 2.6m, Q2 2020 2.6m
12 TRILLIUM THERAPEUTICS INC COM NEW TR TR 2,755,000 $22.3m1.96% 1.96% AddedShares held: Q4 2019 0, Q1 2020 2.4m, Q2 2020 2.8m +311.2k +311,191 12.7%
13 SYNDAX PHARMACEUTICALS INC COM SNDX SNDX 1,320,045 $19.6m1.72% 1.72% AddedShares held: Q4 2019 0, Q1 2020 990.7k, Q2 2020 1.3m +329.3k +329,334 33.2%
14 COLLEGIUM PHARMACEUTICAL INC COM COLL COLL 943,666 $16.5m1.45% 1.45% UnchangedShares held: Q4 2019 1.9m, Q1 2020 943.7k, Q2 2020 943.7k
15 GRITSTONE BIO INC COM GRTS GRTS 2,061,758 $13.7m1.20% 1.20% UnchangedShares held: Q4 2019 2.1m, Q1 2020 2.1m, Q2 2020 2.1m
16 APTINYX INC COM COM 3,190,079 $13.3m1.17% 1.17% UnchangedShares held: Q4 2019 3.2m, Q1 2020 3.2m, Q2 2020 3.2m
17 IVERIC BIO INC COM OPHT OPHT 2,364,500 $12.1m1.06% 1.06% NewShares held: Q4 2019 0, Q1 2020 0, Q2 2020 2.4m
18 ROCKET PHARMACEUTICALS INC COM RCKT RCKT 528,000 $11.1m0.97% 0.97% AddedShares held: Q4 2019 0, Q1 2020 210.0k, Q2 2020 528.0k +318.0k +318,000 151.4%
19 ALLENA PHARMACEUTICALS COM ALNA ALNA 3,330,373 $5.3m0.46% 0.46% UnchangedShares held: Q4 2019 3.3m, Q1 2020 3.3m, Q2 2020 3.3m
20 CIDARA THERAPEUTICS INC COM COM 1,312,258 $4.8m0.43% 0.43% UnchangedShares held: Q4 2019 1.3m, Q1 2020 1.3m, Q2 2020 1.3m
21 NABRIVA THERAPEUTICS PLC SHS NBRV NBRV 4,256,526 $2.9m0.25% 0.25% UnchangedShares held: Q4 2019 4.3m, Q1 2020 4.3m, Q2 2020 4.3m
22 SIERRA ONCOLOGY INC COM NEW COM NEW 202,803 $2.5m0.22% 0.22% UnchangedShares held: Q4 2019 0, Q1 2020 202.8k, Q2 2020 202.8k
23 VTV THERAPEUTICS INC CL A VTVT VTVT 1,062,000 $2.4m0.21% 0.21% UnchangedShares held: Q4 2019 0, Q1 2020 1.1m, Q2 2020 1.1m
24 ITERUM THERAPEUTICS PLC SHS ITRMF ITRMF 1,538,316 $1.8m0.16% 0.16% UnchangedShares held: Q4 2019 1.5m, Q1 2020 1.5m, Q2 2020 1.5m
25 ENTASIS THERAPEUTICS HLDGS I COM COM 349,953 $1.0m0.09% 0.09% ReducedShares held: Q4 2019 1.3m, Q1 2020 1.0m, Q2 2020 350.0k -700.0k -700,000 -66.7%
26 BELLICUM PHARMACEUTICALS INC COM NEW BLCM BLCM 105,144 $781.0k0.07% 0.07% UnchangedShares held: Q4 2019 0, Q1 2020 105.1k, Q2 2020 105.1k

Sold out since Q1 2020

SecurityTickerShares held beforeValue then
MILLENDO THERAPEUTICS INC 1,396,615 $7.4m1.4m shares